Complement deficiency states and associated infections

Molecular Immunology

Volumn 48, Issue 14, 2011, Pages 1643-1655

  Skattum, Lillemor ^a   Van Deuren, Marcel ^b   Van Der Poll, Tom ^c   Truedsson, Lennart ^a  

^a LUND UNIVERSITY   (Sweden)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bacterial infection; Complement; Complement deficiency; Immune defense; Immunodeficiency; Infectious disease

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT FACTOR H; FRESH FROZEN PLASMA; MANNAN BINDING LECTIN; MENINGOCOCCUS VACCINE; SERINE PROTEINASE INHIBITOR;

ADAPTIVE IMMUNITY; CELL ENCAPSULATION; COMPLEMENT DEFICIENCY; COMPLEMENT LECTIN PATHWAY; DISEASE ASSOCIATION; GENETIC DISORDER; HOST RESISTANCE; HUMAN; INFECTION; INFECTION SENSITIVITY; INNATE IMMUNITY; MENINGITIS; NEISSERIACEAE INFECTION; NONHUMAN; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS;

ADAPTIVE IMMUNITY; ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; INFECTION; MANNOSE-BINDING LECTIN; MENINGITIS, PNEUMOCOCCAL; MODELS, IMMUNOLOGICAL; NEISSERIACEAE INFECTIONS; PLASMA EXCHANGE; PNEUMONIA, PNEUMOCOCCAL; RECEPTORS, COMPLEMENT; SEPSIS; VACCINATION;

BACTERIA (MICROORGANISMS);

EID: 79960452978     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.05.001     Document Type: Review

References (177)

1. Afshari A., Wetterslev J., Brok J., Møller A. Antithrombin III for critically ill patients. Cochrane Database Syst. Rev. 2008, 3:CD005370.
2. Agarwal S., Ferreira V.P., Cortes C., Pangburn M.K., Rice P.A., Ram S. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J. Immunol. 2010, 185:507-516.
3. Agostoni A., Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992, 71:206-215.
4. Alper C.A., Xu J., Cosmopoulos K., Dolinski B., Stein R., Uko G., Larsen C.E., Dubey D.P., Densen P., Truedsson L., Sturfelt G., Sjöholm A.G. Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency. J. Clin. Immunol. 2003, 23:297-305.
5. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185:5628-5636.
6. Bang P., Laursen I., Thornberg K., Schierbeck J., Nielsen B., Valdimarsson H., Koch C., Christiansen M. The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia. Scand. J. Infect. Dis. 2008, 40:44-48.
7. Bathum L., Hansen H., Teisner B., Koch C., Garred P., Rasmussen K., Wang P. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol. Immunol. 2006, 43:473-479.
8. Berkel A.I., Birben E., Oner C., Oner R., Loos M., Petry F. Molecular, genetic and epidemiologic studies on selective complete C1q deficiency in Turkey. Immunobiology 2000, 201:347-355.
9. Bjorvatn B., Bjertnaes L., Fadnes H.O., Flaegstad T., Gutteberg T.J., Kristiansen B.E., Pape J., Rekvig O.P., Osterud B., Aanderud L. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br. Med. J. 1984, 288:439-441.
10. Blanch A., Roche O., Urrutia I., Gamboa P., Fontán G., López-Trascasa M. First case of homozygous C1 inhibitor deficiency. J. Allergy Clin. Immunol. 2006, 118:1330-1335. Erratum in 2007. J. Allergy. Clin. Immunol. 119, 745.
11. Brandtzaeg P., Hogasen K., Kierulf P., Mollnes T.E. The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J. Infect. Dis. 1996, 173:647-655.
12. Brandtzaeg P., Mollnes T.E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 1989, 160:58-65.
13. Brandtzaeg P., Sirnes K., Folsland B., Godal H.C., Kierulf P., Bruun J.N., Dobloug J. Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients. Scand. J. Clin. Lab. Invest. Suppl. 1985, 178:53-55.
14. Brodsky R.A. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2008, 22:65-74.
15. Brouwer N., Frakking F.N., van de Wetering M.D., van Houdt M., Hart M., Budde I.K., Strengers P.F., Laursen I., Houen G., Roos D., Jensenius J.C., Caron H.N., Dolman K.M., Kuijpers T.W. Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels. J. Immunol. 2009, 183:3496-3504.
16. Brown J.S., Hussell T., Gilliland S.M., Holden D.W., Paton J.C., Ehrenstein M.R., Walport M.J., Botto M. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16969-16974.
17. Brown K.S., Ryder S.D., Irving W.L., Sim R.B., Hickling T.P. Mannan binding lectin and viral hepatitis. Immunol. Lett. 2007, 108:34-44.
18. Carlsson M., Sjöholm A.G., Eriksson L., Thiel S., Jensenius J.C., Segelmark M., Truedsson L. Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clin. Exp. Immunol. 2005, 139:306-313.
19. Cates K.L., Densen P., Lockman J.C., Levine R.P. C4B deficiency is not associated with meningitis or bacteremia with encapsulated bacteria. J. Infect. Dis. 1992, 16:942-944.
20. CDC Advisory Committee on Immunization Practices (ACIP) 2010, 2011. Updated recommendations for use of meningococcal conjugate vaccines. MMWR Morb. Mortal. Wkly. Rep. 60, 72-76.
21. Cerquetti M.C., Sordelli D.O., Ortegon R.A., Bellanti J.A. Impaired lung defenses against Staphylococcus aureus in mice with hereditary deficiency of the fifth component of complement. Infect. Immun. 1983, 41:1071-1076.
22. Cicardi M., Zanichelli A. Acquired angioedema. Allergy Asthma Clin. Immunol. 2010, 6:14.
23. Cockburn I.A., Mackinnon M.J., O'Donnell A., Allen S.J., Moulds J.M., Baisor M., Bockarie M., Reeder J.C., Rowe J.A. A human CR1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:272-277.
24. Cooper N.R., Nemerow G.R. The role of antibody and complement in the control of viral infections. J. Invest. Dermatol. 1984, 83:121-127.
25. Cortes-Hernandez J., Fossati-Jimack L., Petry F., Loos M., Izui S., Walport M.J., Cook H.T., Botto M. Restoration of C1q levels by bone marrow transplantation attenuates autoimmune disease associated with C1q deficiency in mice. Eur. J. Immunol. 2004, 34:3713-3722.
26. Crawford D.C., Zimmer S.M., Morin C.A., Messonnier N.E., Lynfield R., Yi Q., Shephard C., Wong M., Rieder M.J., Livingston R.J., Nickerson D.A., Whitney C.G., Lingappa J. Integrating host genomics with surveillance for invasive bacterial diseases. Emerg. Infect. Dis. 2008, 14:1138-1140.
27. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., Schmal H., Friedl H.P., Ward P.A. Protective effects of C5a blockade in sepsis. Nat. Med. 1999, 5:788-792.
28. Daha M.R. Role of complement in innate immunity and infections. Crit. Rev. Immunol. 2010, 30:4752.
29. Dahlke K., Wrann C.D., Sommerfeld O., Soßdorf M., Recknagel P., Sachse S., Winter S.W., Klos A., Stahl G.L., Ma Y.X., Claus R.A., Reinhart K., Bauer M., Riedemann N.C. Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis. J. Immunol. 2011, 186:3066-3075.
30. Davin J.C., Buter N., Groothoff J., van Wijk J., Bouts A., Strain L., Goodship T. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr. Nephrol. 2009, 24:1757-1760.
31. Davis A.E. Hereditary angioedema: a current state-of-the-art review. III: mechanisms of hereditary angioedema. Ann. Allergy Asthma Immunol. 2008, 100(1 Suppl. 2):S7-S12.
32. Davis A.E., Lu F., Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost. 2010, 104:886-893.
33. de Jong H.K., van der Poll T., Wiersinga W.J. The systemic pro-inflammatory response in sepsis. J. Innate. Immun. 2010, 2:422-430.
34. de Kleijn E.D., de Groot R., Hack C.E., Mulder P.G., Engl W., Moritz B., Joosten K.F., Hazelzet J.A. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit. Care Med. 2003, 31:1839-1847.
35. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002, 46:2294-2300.
36. Dragon-Durey M.A., Frémeaux-Bacchi V., Loirat C., Blouin J., Niaudet P., Deschenes G., Coppo P., Herman Fridman W., Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 2004, 15:787-795.
37. Dragon-Durey M.A., Quartier P., Frémeaux-Bacchi V., Blouin J., de Barace C., Prieur A.M., Weiss L., Fridman W.H. Molecular basis of a selective C1s deficiency associated with early onset multiple autoimmune diseases. J. Immunol. 2001, 166:7612-7616.
38. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell. Res. 2010, 20:34-50.
39. Dzwonek A., Novelli V., Bajaj-Elliott M., Turner M., Clapson M., Klein N. Mannose-binding lectin in susceptibility and progression of HIV-1 infection in children. Antivir. Ther. 2006, 11:499-505.
40. Fakhouri F., de Jorge E.G., Brune F., Azam P., Cook H.T., Pickering M.C. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int. 2010, 78:279-286.
41. Fevang B., Mollnes T.E., Holm A.M., Ueland T., Heggelund L., Damas J.K., Aukrust P., Froland S.S. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin. Exp. Immunol. 2005, 142:576-584.
42. Figueroa J.E., Densen P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 1991, 4:359-395.
43. Fijen C.A., Kuijper E.J., Drogari-Apiranthitou M., Van Leeuwen Y., Daha M.R., Dankert J. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin. Exp. Immunol. 1998, 114:362-369.
44. Fijen C.A., Kuijper E.J., Hannema A.J., Sjöholm A.G., van Putten J.P. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet 1989, 2:585-588.
45. Fijen C.A., Kuijper E.J., te Bulte M.T., Daha M.R., Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin. Infect. Dis. 1999, 28:98-105.
46. Fijen C.A., van den Bogaard R., Schipper M., Mannens M., Schlesinger M., Nordin F.G., Dankert J., Daha M.R., Sjöholm A.G., Truedsson L., Kuijper E.J. Properdin deficiency: molecular basis and disease association. Mol. Immunol. 1999, 36:863-867.
47. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:4510-4514.
48. Frakking F.N., Brouwer N., van de Wetering M.D., Budde I.K., Strengers P.F., Huitema A.D., Laursen I., Houen G., Caron H.N., Dolman K.M., Kuijpers T.W. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia. Eur. J. Cancer 2009, 45:505-512.
49. Frank M.M., Joiner K., Hammer C. The function of antibody and complement in the lysis of bacteria. Rev. Infect. Dis. 1987, 9(Suppl 5):537-545.
50. Frederiksen P.D., Thiel S., Larsen C.B., Jensenius J.C. M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand. J. Immunol. 2005, 62:462-473.
51. Fritsche L.G., Lauer N., Hartmann A., Stippa S., Keilhauer C.N., Oppermann M., Pandey M.K., Köhl J., Zipfel P.F., Weber B.H., Skerka C. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum. Mol. Genet. 2010, 19:4694-4704.
52. Fukumori Y., Yoshimura K., Ohnoki S., Yamaguchi H., Akagaki Y., Inai S. A high incidence of C9 deficiency among healthy blood donors in Osaka. Jpn. Int. Immunol. 1989, 1:85-89.
53. Garred P., Larsen F., Seyfarth J., Fujita R., Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7:85-94.
54. Garred P., Pressler T., Lanng S., Madsen H.O., Moser C., Laursen I., Balstrup F., Koch C. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr. Pulmonol. 2002, 33:201-207.
55. Garred P., Pressler T., Madsen H.O., Frederiksen B., Svejgaard A., Høiby N., Schwartz M., Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 1999, 104:431-437.
56. Genel F., Sjöholm A.G., Skattum L., Truedsson L. Complement factor I deficiency associated with recurrent infections, vasculitis and immune complex glomerulonephritis. Scand. J. Infect. Dis. 2005, 37:615-618.
57. Ghannam A., Pernollet M., Fauquert J.L., Monnier N., Ponard D., Villiers M.B., Péguet-Navarro J., Tridon A., Lunardi J., Gerlier D., Drouet C. Human C3 deficiency associated with impairments in dendritic cell differentiation, memory B cells, and regulatory T cells. J. Immunol. 2008, 181:5158-5166.
58. Gilliam B.E., Wolff A.E., Moore T.L. Partial C4 deficiency in juvenile idiopathic arthritis patients. J. Clin. Rheumatol. 2007, 13:256-260.
59. Gorgani N.N., He J.Q., Katschke K.J., Helmy K.Y., Xi H., Steffek M., Hass P.E., van Lookeren, Campagne M. Complement receptor of the Ig superfamily enhances complement-mediated phagocytosis in a subpopulation of tissue resident macrophages. J. Immunol. 2008, 181:7902-7908.
60. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 2009, 77:764-769.
61. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
62. Hack C.E., Ogilvie A.C., Eisele B., Eerenberg A.J., Wagstaff J., Thijs L.G. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 1993, 19(Suppl. 1):S19-S28.
63. Halle D., Elstein D., Geudalia D., Sasson A., Shinar E., Schlesinger M., Zimran A. High prevalence of complement C7 deficiency among healthy blood donors of Moroccan Jewish ancestry. Am. J. Med. Genet. 2001, 99:325-327.
64. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'dwyer C., Langford P.R., Simon Kroll J., Levin M. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand. J. Infect. Dis. 2006, 38:764-771.
65. Hellemann D., Larsson A., Madsen H.O., Bonde J., Jarløv J.O., Wiis J., Faber T., Wetterslev J., Garred P. Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients. Hum. Mol. Genet. 2007, 16:3071-3080.
66. Hart M.L., Saifuddin M., Uemura K., Bremer E.G., Hooker B., Kawasaki T., Spear G.T. High mannose glycans and sialic acid on gp120 regulate binding of mannose-binding lectin (MBL) to HIV type 1. AIDS Res. Hum. Retroviruses 2002, 18:1311-1317.
67. Hiemstra P.S., Langeler E., Compier B., Keepers Y., Leijh P.C., van den Barselaar M.T., Overbosch D., Daha M.R. Complete and partial deficiencies of complement factor D in a Dutch family. J. Clin. Invest. 1989, 84:1957-1961.
68. Hirsch R.L., Griffin D.E., Winkelstein J.A. Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. J. Immunol. 1981, 127:1740-1743.
69. Höpken U.E., Lu B., Gerard N.P., Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996, 383:86-89.
70. Huber-Lang M.S., Sarma J.V., McGuire S.R., Lu K.T., Guo R.F., Padgaonkar V.A., Younkin E.M., Laudes I.J., Riedemann N.C., Younger J.G., Ward P.A. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J. 2001, 15:568-570.
71. Hudson-Peacock M.J., Joseph S.A., Cox J., Munro C.S., Simpson N.B. Systemic lupus erythematosus complicating complement type 2 deficiency: successful treatment with fresh frozen plasma. Br. J. Dermatol. 1997, 136:388-392.
72. Jaatinen T., Ruuskanen O., Truedsson L., Lokki M.L. Homozygous deletion of the CYP21A-TNXA-RP2-C4B gene region conferring C4B deficiency associated with recurrent respiratory infections. Hum. Immunol. 1999, 60:707-714.
73. Jensenius J.C., Jensen P.H., McGuire K., Larsen J.L., Thiel S. Recombinant mannan-binding lectin (MBL) for therapy. Biochem. Soc. Trans. 2003, 31:763-767.
74. Ji X., Olinger G.G., Aris S., Chen Y., Gewurz H., Spear G.T. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J. Gen. Virol. 2005, 86:2535-2542.
75. Johnson C.A., Densen P., Wetsel R.A., Cole F.S., Goeken N.E., Colten H.R. Molecular heterogeneity of C2 deficiency. N. Engl. J. Med. 1992, 326:871-874.
76. Jönsson G., Oxelius V.A., Truedsson L., Braconier J.H., Sturfelt G., Sjöholm A.G. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J. Immunol. 2006, 177:722-728.
77. Jönsson G., Sjöholm A.G., Truedsson L., Bengtsson A.A., Braconier J.H., Sturfelt G. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology (Oxford) 2007, 46:1133-1139.
78. Jönsson G., Truedsson L., Sturfelt G., Oxelius V.A., Braconier J.H., Sjöholm A.G. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 2005, 84:23-34.
79. Kakkanaiah V.N., Shen G.Q., Ojo-Amaize E.A., Peter J.B. Association of low concentrations of serum mannose-binding protein with recurrent infections in adults. Clin. Diagn. Lab. Immunol. 1998, 5:319-321.
80. Kallel-Sellami M., Blouin J., Abdelmalek R., Laadhar L., Zerzeri Y., Barbouche M.R., Tiouiri H., Chaabène T., Fremeaux-Bacchi V., Zitouni M., Makni S. Disseminated tuberculosis in a patient with hereditary C1-inhibitor deficiency. Infection 2008, 36:181-183.
81. Kapetanovic M.C., Saxne T., Sjöholm A., Truedsson L., Jönsson G., Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
82. Kaplan A.P., Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol. Immunol. 2010, 47:2161-2169.
83. Karp C.L., Wysocka M., Wahl L.M., Ahearn J.M., Cuomo P.J., Sherry B., Trinchieri G., Griffin D.E. Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996, 273:228-231.
84. Kerr A.R., Paterson G.K., Riboldi-Tunnicliffe A., Mitchell T.J. Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3. Infect. Immun. 2005, 73:4245-4252.
85. Kilpatrick D.C. Consensus statement on the future of mannan-binding lectin (MBL)-replacement therapy. Biochem. Soc. Trans. 2003, 31:776.
86. Kim A.H., Dimitriou I.D., Holland M.C., Mastellos D., Mueller Y.M., Altman J.D., Lambris J.D., Katsikis P.D. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J. Immunol. 2004, 173:2524-2529.
87. Knutzen Steuer K.L., Sloan L.B., Oglesby T.J., Farries T.C., Nickells M.W., Densen P., Harley J.B., Atkinson J.P. Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement. J. Immunol. 1989, 143:2256-2261.
88. Kolla R.V., Chintalapati S., Sabet M., Santelli E., Liddington R.C., David M., Fierer J., Guiney D., Rickert R.C. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS One 2007 Oct 17, 2(10):e1044.
89. Kopf M., Abel B., Gallimore A., Carroll M., Bachmann M.F. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 2002, 8:373-378.
90. Lappegård K.T., Christiansen D., Pharo A., Thorgersen E.B., Hellerud B.C., Lindstad J., Nielsen E.W., Bergseth G., Fadnes D., Abrahamsen T.G., Hoiby E.A., Schejbel L., Garred P., Lambris J.D., Harboe M., Mollnes T.E. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15861-15866.
91. Laudes I.J., Chu J.C., Sikranth S., Huber-Lang M., Guo R.F., Riedemann N., Sarma J.V., Schmaier A.H., Ward P.A. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 2002, 160:1867-1875.
92. Laursen I., Houen G., Hojrup P., Brouwer N., Krogsoe L.B., Blou L., Hansen P.R. Second-generation nanofiltered plasma-derived mannan-binding lectin product: process and characteristics. Vox Sang. 2007, 92:338-350.
93. Laursen I. Mannan-binding lectin (MBL) production from human plasma. Biochem. Soc. Trans. 2003, 31:758-762.
94. Licht C., Weyersberg A., Heinen S., Stapenhorst L., Devenge J., Beck B., Waldherr R., Kirschfink M., Zipfel P.F., Hoppe B. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am. J. Kidney Dis. 2005, 45:415-421.
95. Lint T.F., Zeitz H.J., Gewurz H. Inherited deficiency of the ninth component of complement in man. J. Immunol. 1980, 125:2252-2257.
96. Lipsker D., Hauptmann G. Cutaneous manifestations of complement deficiencies. Lupus 2010, 19:1096-1106.
97. Lo H., Tang C.M., Exley R.M. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect. Dis. 2009, 9:418-427.
98. Madsen H.O., Videm V., Svejgaard A., Svennevig J.L., Garred P. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet 1998, 352:959-960.
99. Marti-Carvajal A.J., Solà I., Lathyris D., Cardona A.F. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst. Rev. 2011, 4:CD004388.
100. Martini P.G., Cook L.C., Alderucci S., Norton A.W., Lundberg D.M., Fish S.M., Langsetmo K., Jönsson G., Lood C., Gullstrand B., Zaleski K.J., Savioli N., Lottherand J., Bedard C., Gill J., Concino M.F., Heartlein M.W., Truedsson L., Powell J.L., Tzianabos A.O. Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. BMC Immunol. 2010, 11:43.
101. Mehta P., Norsworthy P.J., Hall A.E., Kelly S.J., Walport M.J., Botto M., Pickering M.C. SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology 2010, 49:823-824.
102. Michelow I.C., Lear C., Scully C., Prugar L.I., Longley C.B., Yantosca L.M., Ji X., Karpel M., Brudner M., Takahashi K., Spear G.T., Ezekowitz R.A., Schmidt E.V., Olinger G.G. High-dose mannose-binding lectin therapy for ebola virus infection. J. Infect. Dis. 2011, 203:175-179.
103. Mougey R. A review of the Chido/Rodgers blood group. Immunohematology 2010, 26:30-38.
104. Mueller-Ortiz S.L., Drouin S.M., Wetsel R.A. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect. Immun. 2004, 72:2899-2906.
105. Mullighan C.G., Heatley S.L., Danner S., Dean M.M., Doherty K., Hahn U., Bradstock K.F., Minchinton R., Schwarer A.P., Szer J., Bardy P.G. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 2008, 112:2120-2128.
106. Mullighan C.G., Marshall S.E., Welsh K.I. Mannose binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency. Scand. J. Immunol. 2000, 51:111-122.
107. Munthe-Fog L., Hummelshøj T., Honoré C., Madsen H.O., Permin H., Garred P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N. Engl. J. Med. 2009, 360:2637-2644.
108. Nagata M., Hara T., Aoki T., Mizuno Y., Akeda H., Inaba S., Tsumoto K., Ueda K. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis. J. Pediatr. 1989, 114:260-264.
109. Nasraway S.A. The problems and challenges of immunotherapy in sepsis. Chest 2003, 123. 451S-459S.
110. Nilsson S.C., Trouw L.A., Renault N., Miteva M.A., Genel F., Zelazko M., Marquart H., Muller K., Sjöholm A.G., Truedsson L., Villoutreix B.O., Blom A.M. Genetic, molecular and functional analyses of complement factor I deficiency. Eur. J. Immunol. 2009, 39:310-323.
111. Nita, I.M., Genel, F., Nilsson, S.C., Smart, J., Truedsson, L., Choo, S., Blom, A.M., 2011. Molecular characterization of two novel cases of complete complement inhibitor Factor I deficiency. Mol. Immunol. [Epub ahead of print].
112. Osofsky S.G., Thompson B.H., Lint T.F., Gewurz H. Hereditary deficiency of the third component of complement in a child with fever, skin rash, and arthralgias: response to transfusion of whole blood. J. Pediatr. 1977, 90:180-186.
113. Osterud B. Meningococcal septicemia: the use of plasmapheresis or blood exchange and how to detect severe endotoxin induced white cell activation. Scand. J. Clin. Lab. Invest. Suppl. 1985, 178:47-51.
114. Paul R., Obermaier B., Van Ziffle J., Angele B., Pfister H.W., Lowell C.A., Koedel U. Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase. J. Leukoc. Biol. 2008, 84:1141-1150.
115. Pesonen E., Hallman M., Sarna S., Andsberg E., Haataja R., Meri S., Persson K., Puolakkainen M., Ohlin H., Truedsson L. Mannose-binding lectin as a risk factor for acute coronary syndromes. Ann. Med. 2009, 41:591-598.
116. Petersen K.A., Matthiesen F., Agger T., Kongerslev L., Thiel S., Cornelissen K., Axelsen M. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J. Clin. Immunol. 2006, 26:465-475.
117. Petry F. Molecular basis of hereditary C1q deficiency. Immunobiology 1998, 199:286-294.
118. Pettigrew H.D., Teuber S.S., Gershwin M.E. Clinical significance of complement deficiencies. Ann. N. Y. Acad. Sci. 2009, 1173:108-123.
119. Platonov A.E., Beloborodov V.B., Vershinina I.V. Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore) 1993, 72:374-392.
120. Platonov A.E., Vershinina I.V., Käyhty H., Fijen C.A., Würzner R., Kuijper E.J. Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients. Int. Arch. Allergy Immunol. 2003, 130:314-321.
121. Rabiet M.J., Huet E., Boulay F. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 2007, 89:1089-1106.
122. Rabs U., Martin H., Hitschold T., Golan M.D., Heinz H.P., Loos M. Isolation and characterization of macrophage-derived C1q and its similarities to serum C1q. Eur. J. Immunol. 1986, 16:1183-1186.
123. Ram S., Lewis L.A., Rice P.A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 2010, 23:740-780.
124. Reis E.S., Falcão D.A., Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 2006, 63:155-168.
125. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
126. Riedemann N.C., Guo R.F., Neff T.A., Laudes I.J., Keller K.A., Sarma V.J., Markiewski M.M., Mastellos D., Strey C.W., Pierson C.L., Lambris J.D., Zetoune F.S., Ward P.A. Increased C5a receptor expression in sepsis. J. Clin. Invest. 2002, 110:101-108.
127. Rijneveld A.W., de Vos A.F., Florquin S., Verbeek J.S., van der Poll T. CD11b limits bacterial outgrowth and dissemination during murine pneumococcal pneumonia. J. Infect. Dis. 2005, 191:1755-1760.
128. Rorvig S., Honore C., Larsson L.I., Ohlsson S., Pedersen C.C., Jacbsen L.C., Cowland J.B., Garred P., Borregaard N. Ficolin-1 is present in a highly mobilizable subset of human neutrophil granules and associates with the cell surface after stimulation with fMLP. J. Leukoc. Biol. 2009, 86:1439-1449.
129. Roumenina L.T., Loirat C., Dragon-Durey M.A., Halbwachs-Mecarelli L., Sautes-Fridman C., Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 2011, 365:8-26.
130. Rowe P.C., McLean R.H., Wood R.A., Leggiadro R.J., Winkelstein J.A. Association of homozygous C4B deficiency with bacterial meningitis. J. Infect. Dis. 1989, 160:448-451.
131. Ruiz-Irastorza G., Olivares N., Ruiz-Arruza I., Martinez-Berriotxoa A., Egurbide M.V., Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 2009, 11:R109.
132. Rupprecht T.A., Angele B., Klein M., Heesemann J., Pfister H.W., Botto M., Koedel U. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J. Immunol. 2007, 178:1861-1869.
133. Rutkowski M.J., Sughrue M.E., Kane A.J., Ahn B.J., Fang S., Parsa A.T. The complement cascade as a mediator of tissue growth and regeneration. Inflamm. Res. 2010, 59:897-905.
134. Saifuddin M., Hart M.L., Gewurz H., Zhang Y., Spear G.T. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J. Gen. Virol. 2000, 81:949-955.
135. Schejbel L., Rosenfeldt V., Marquart H., Valerius N.H., Garred P. Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome. Clin. Immunol. 2009, 131:456-462.
136. Schejbel, L., Skattum, L., Åhlin, A., Hagelberg, S., Schiller, B., Genel, F., Truedsson, L., Garred, P., 2011. Molecular basis of hereditary C1q deficiency-revisited: Identification of several novel disease causing mutations. Genes Immun., in press.
137. Schlesinger M., Greenberg R., Levy J., Kayhty H., Levy R. Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency. J. Infect. Dis. 1994, 170:449-453.
138. Selander B., Mårtensson U., Weintraub A., Holmström E., Matsushita M., Thiel S., Jensenius J.C., Truedsson L., Sjöholm A.G. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 2006, 116:1425-1434.
139. Shi L., Takahashi K., Dundee J., Shahroor-Karni S., Thiel S., Jensenius J.C., Gad F., Hamblin M.R., Sastry K.N., Ezekowitz R.A. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J. Exp. Med. 2004, 199:1379-1390.
140. Silasi-Mansat R., Zhu H., Popescu N.I., Peer G., Sfyroera G., Magotti P., Ivanciu L., Lupu C., Mollnes T.E., Taylor F.B., Kinasewitz G., Lambris J.D., Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010.
141. Singer M., Jones A.M. Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit. Care 2011, 15:203.
142. Sjöholm A.G., Braconier J.H., Söderström C. Properdin deficiency in a family with fulminant meningococcal infections. Clin. Exp. Immunol. 1982, 50:291-297.
143. Sjöholm A.G., Jönsson G., Braconier J.H., Sturfelt G., Truedsson L. Complement deficiency and disease: an update. Mol. Immunol. 2006, 43:78-85.
144. Skattum L., Gullstrand B., Holmström E., Oxelius V.A., Truedsson L. Serum bactericidal activity against Neisseria meningitidis in patients with C3 nephritic factors is dependent on IgG allotypes. Clin. Immunol. 2008, 129:123-131.
145. Spadafora C., Awandare G.A., Kopydlowski K.M., Czege J., Moch J.K., Finberg R.W., Tsokos G.C., Stoute J.A. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PLoS Pathog. 2010, 6:e1000968.
146. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600-2608.
147. Sprong T., Mollnes T.E., Neeleman C., Swinkels D., Netea M.G., van der Meer J.W., van Deuren M. Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clin. Infect. Dis. 2009, 49:1380-1386.
148. Sprong T., Roos D., Weemaes C., Neeleman C., Geesing C.L., Mollnes T.E., van Deuren M. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006, 107:4865-4870.
149. Steinsson K., Erlendsson K., Valdimarsson H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum. 1989, 32:906-913.
150. Stengaard-Pedersen K., Thiel S., Gadjeva M., Møller-Kristensen M., Sørensen R., Jensen L.T., Sjöholm A.G., Fugger L., Jensenius J.C. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 2003, 349:554-560.
151. Sumiya M., Super M., Tabona P., Levinsky R.J., Arai T., Turner M.W., Summerfield J.A. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991, 337:1569-1570.
152. Summerfield J.A. Clinical potential of mannose-binding lectin-replacement therapy. Biochem. Soc. Trans. 2003, 31:770-773.
153. Super M., Thiel S., Lu J., Levinsky R.J., Turner M.W. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989, 2:1236-1239.
154. Tedesco F. Inherited complement deficiencies and bacterial infections. Vaccine 2008, 26(Suppl. 8):I3-I8.
155. Thiel S., Steffensen R., Christensen I.J., Ip W.K., Lau Y.L., Reason I.J., Eiberg H., Gadjeva M., Ruseva M., Jensenius J.C. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun. 2007, 8:154-163.
156. Toledo R.G., Da Silva W.D., Calich V.L., Kipnis T.L. Mannose-binding lectin complement pathway plays a key role in complement activation by Paracoccidioides brasiliensis. Mol. Immunol. 2010, 48:26-36.
157. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40:560-566.
158. Tuomanen E., Hengstler B., Zak O., Tomasz A. The role of complement in inflammation during experimental pneumococcal meningitis. Microb. Pathog. 1986, 1:15-32.
159. Valdimarsson H., Stefansson M., Vikingsdottir T., Arason G.J., Koch C., Thiel S., Jensenius J.C. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand. J. Immunol. 1998, 48:116-123.
160. Valdimarsson H., Vikingsdottir T., Bang P., Saevarsdottir S., Gudjonsson J.E., Oskarsson O., Christiansen M., Blou L., Laursen I., Koch C. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand. J. Immunol. 2004, 59:97-102.
161. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem. Soc. Trans. 2003, 31:768-769.
162. van den Heuvel-Eibrink M.M., Bredius R.G., te Winkel M.L., Tamminga R., de Kraker J., Schouten-van Meeteren A.Y., Bruin M., Korthof E.T. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br. J. Haematol. 2005, 128:571-577.
163. van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect. Dis. 2008, 8:32-43.
164. van der Poll T., Opal S.M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374:1543-1556.
165. van Deuren M., Santman F.W., van Dalen R., Sauerwein R.W., Span L.F., van der Meer J.W. Plasma and whole blood exchange in meningococcal sepsis. Clin. Infect. Dis. 1992, 15:424-430.
166. Vassallo G., Newton R.W., Chieng S.E., Haeney M.R., Shabani A., Arkwright P.D. Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency. Rheumatology (Oxford) 2007, 46:1612-1614.
167. von Köckritz-Blickwede M., Konrad S., Foster S., Gessner J.E., Medina E. Protective role of complement C5a in an experimental model of Staphylococcus aureus bacteremia. J. Innate. Immun. 2009, 2:87-92.
168. Vorup-Jensen T., Sorensen E.S., Jensen U.B., Schwaeble W., Kawasaki T., Ma Y., Uemura K., Wakamiya N., Suzuki Y., Jensen T.G., Takahashi K., Ezekowitz R.A., Thiel S., Jensenius J.C. Recombinant expression of human mannan-binding lectin. Int. Immunopharmacol. 2001, 1:677-687.
169. Ward P.A. Role of the complement in experimental sepsis. J. Leukoc. Biol. 2008, 83:467-470.
170. Westendorp R.G., Brand A., Haanen J., van Hinsbergh V.W., Thompson J., van Furth R., Meinders E.A. Leukaplasmapheresis in meningococcal septic shock. Am. J. Med. 1992, 92:577-578.
171. Windbichler M., Echtenacher B., Hehlgans T., Jensenius J.C., Schwaeble W., Mannel D.N. Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect. Immun. 2004, 72:5247-5252.
172. Winkelstein J.A. The role of complement in the host's defense against Streptococcus pneumoniae. Rev. Infect. Dis. 1981, 3:289-298.
173. Würzner R., Hobart M.J., Fernie B.A., Mewar D., Potter P.C., Orren A., Lachmann P.J. Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6. J. Clin. Invest. 1995, 95:1877-1883.
174. Yang Y., Chung E.K., Wu Y.L., Savelli S.L., Nagaraja H.N., Zhou B., Hebert M., Jones K.N., Shu Y., Kitzmiller K., Blanchong C.A., McBride K.L., Higgins G.C., Rennebohm R.M., Rice R.R., Hackshaw K.V., Roubey R.A., Grossman J.M., Tsao B.P., Birmingham D.J., Rovin B.H., Hebert L.A., Yu C.Y. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am. J. Hum. Genet. 2007, 80:1037-1054.
175. Yu C.Y. Molecular genetics of the human MHC complement gene cluster. Exp. Clin. Immunogenet. 1998, 15:213-230.
176. Yuste J., Sen A., Truedsson L., Jönsson G., Tay L.S., Hyams C., Baxendale H.E., Goldblatt F., Botto M., Brown J.S. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect. Immun. 2008, 76:3761-3770.
177. Zhu Z., Atkinson T.P., Hovanky K.T., Boppana S.B., Dai Y.L., Densen P., Go R.C., Jablecki J.S., Volanakis J.E. High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA. Clin. Exp. Immunol. 2000, 119:305-310.